Cubist Pharmaceuticals, Inc.
http://www.cubist.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cubist Pharmaceuticals, Inc.
GlycoMimetics Forges Ahead With Uproleselan In AML After Phase III Failure
The company said an NCI trial and a China study remain ongoing despite a Phase III study in relapsed/refractory disease failing, with an unusually long OS result in the control arm.
Asia Deal Watch: Ono Inks Partnerships With Switzerland’s Numab, US Biotech Shattuck
Plus alliances involving Xyphos/Kelonia, Nippon Shinyaku/Vicor, Telix/QSAM, Nicox/Kowa, Kyowa Kirin/BridgeBio, as well as deals in brief.
Breaking The Pain Market’s Addiction To Opioids
The recent success of Vertex in acute pain merely highlights the agonizingly slow process elsewhere, particularly in chronic pain indications.
US FDA Oncology Diagnostics Pilot Is ‘Interim Step’ To Fill VALID Void, But ‘Stuck In Neutral’
Without sponsors willing to work with them and in the absence of legislation giving FDA authority over lab-developed tests, the agency has launched internal programs to both gain more oversight – and spur innovation.
Company Information
- Industry
- Biotechnology
- Other Names / Subsidiaries
-
- Adolor Corporation (ADLR)
- Calixa Therapeutics, Inc.
- Optimer Pharmaceuticals, Inc.
- Trius Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice